help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by SNYDER, D. C.
Right arrow Articles by CHIN, D. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by SNYDER, D. C.
Right arrow Articles by CHIN, D. P.

Am. J. Respir. Crit. Care Med., Volume 160, Number 2, August 1999, 582-586

Cost-effectiveness Analysis of Directly Observed Therapy for Patients with Tuberculosis at Low Risk for Treatment Default

DAVID C. SNYDER and DANIEL P. CHIN

California Department of Health Services, Tuberculosis Control Branch, Berkeley; and Francis J. Curry National Tuberculosis Center, San Francisco, California

To determine the incremental cost of directly observed therapy (DOT) for patients with tuberculosis at low risk for treatment default, we applied a model of DOT effectiveness to 1,377 low-risk patients in California during 1995. The default rate for this cohort, which consisted of those with no recent history of substance abuse, homelessness, or incarceration, was 1.7%. The model predicted that DOT and self-administered therapy (SAT) cured 93.1 and 90.8% of these patients, respectively. DOT would initially cost $1.83 million more than SAT, but avert $569,191 in treatment cost for relapse cases and their contacts, for a net incremental cost of $1.27 million ($919 per patient treated), or $40,620 per additional case cured. The cost-effectiveness of DOT was sensitive to the default rate and relapse rate after completing SAT. DOT would generate cost savings only when the default and relapse rates were more than 32.2 and 9.2%, respectively. Given the low default rate and resulting high incremental cost of DOT, provision of DOT to low-risk patients in California should be evaluated in the context of resource availability, competing program priorities, and program success in completing self-administered therapy with a low relapse rate.




This article has been cited by other articles:


Home page
 PediatricsHome page
V. J. Flaherman, T. C. Porco, E. Marseille, and S. E. Royce
Cost-effectiveness of Alternative Strategies for Tuberculosis Screening Before Kindergarten Entry
Pediatrics, July 1, 2007; 120(1): 90 - 99.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
R. M. JASMER, D. C. SNYDER, D. P. CHIN, P. C. HOPEWELL, S. S. CUTHBERT, E. ANTONIO PAZ, and C. L. DALEY
Twelve Months of Isoniazid Compared with Four Months of Isoniazid and Rifampin for Persons with Radiographic Evidence of Previous Tuberculosis . An Outcome and Cost-Effectiveness Analysis
Am. J. Respir. Crit. Care Med., November 1, 2000; 162(5): 1648 - 1652.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 1999 American Thoracic Society